Audax Biosciences

Audax Biosciences is a preclinical-stage biotechnology company dedicated to the discovery and development of first-in-class therapeutics for metabolic diseases, such as type 2 diabetes and obesity. The company's lead research program focuses on neutralizing asprosin, a protein hormone that triggers the liver to release glucose into the bloodstream and crosses the blood-brain barrier to stimulate appetite. By inhibiting asprosin, Audax aims to provide a dual-action treatment that improves glycemic control and promotes weight loss. Founded by experts in metabolic endocrinology, the company leverages deep insights into the gut-brain axis to address the growing global burden of metabolic syndrome. The firm is currently advancing its lead candidate through early development stages to validate its mechanism in human clinical trials.